Pfizer Ltd. Technical Momentum Shifts to Sideways; Mojo Grade Upgraded to Hold

Technical Trend Evolution and Price Movement

Pfizer’s current price stands at ₹4,915.45, up from the previous close of ₹4,822.80, marking a daily increase of 1.92%. The stock traded within a range of ₹4,810.55 to ₹4,934.90 today, remaining below its 52-week high of ₹5,878.55 but comfortably above the 52-week low of ₹4,361.00. This price action suggests a consolidation phase following earlier volatility, with the technical trend shifting from mildly bearish to sideways, indicating a pause in downward momentum and potential for stabilisation.

MACD and Momentum Indicators: Mixed Signals

The Moving Average Convergence Divergence (MACD) indicator presents a dichotomy between weekly and monthly timeframes. On a weekly basis, the MACD is mildly bullish, signalling a potential short-term upward momentum. Conversely, the monthly MACD remains mildly bearish, reflecting longer-term caution among investors. This divergence suggests that while near-term price action may be improving, the broader trend still warrants vigilance.

The Know Sure Thing (KST) indicator aligns with this mixed view, showing mild bullishness on the weekly chart but mild bearishness monthly. Such oscillations in momentum indicators highlight the stock’s current indecision phase, where short-term gains may be tempered by longer-term uncertainties.

RSI and Bollinger Bands: Stability Amid Volatility

The Relative Strength Index (RSI) on both weekly and monthly charts shows no definitive signal, hovering in neutral territory. This lack of overbought or oversold conditions suggests that Pfizer’s price is neither stretched nor deeply discounted, supporting the sideways trend narrative.

Meanwhile, Bollinger Bands indicate bullishness on both weekly and monthly timeframes. The stock price is trading near the upper band on the weekly chart, implying increased buying interest and potential for further upside in the short term. The monthly bullish Bollinger Bands reinforce this positive technical backdrop, signalling that volatility remains contained within an upward channel.

Moving Averages and Dow Theory: Cautious Optimism

Daily moving averages currently show a mildly bearish stance, reflecting recent price softness relative to short-term averages. However, the Dow Theory readings on both weekly and monthly charts are mildly bullish, suggesting that the broader market trend for Pfizer is improving. This combination points to a scenario where short-term price dips may offer entry points within an overall positive trend framework.

Volume and On-Balance Volume (OBV) Analysis

On-Balance Volume (OBV) indicators on weekly and monthly scales show no clear trend, indicating that volume flow has not decisively confirmed price movements. This absence of volume confirmation tempers enthusiasm, as sustained price moves typically require strong volume support to validate momentum shifts.

Comparative Returns and Market Context

Pfizer’s recent returns outperform the Sensex benchmark over short and medium terms. The stock has delivered a 4.80% return over the past week and a 7.67% gain over the last month, compared to Sensex returns of 2.35% and 1.13% respectively. Year-to-date, Pfizer’s return is -1.35%, outperforming the Sensex’s -7.72%, while over one year, the stock’s decline of -2.68% slightly trails the Sensex’s -2.43% fall.

Longer-term performance shows mixed results: a robust 23.04% gain over three years surpasses the Sensex’s 20.54%, but a five-year return of -17.26% lags significantly behind the Sensex’s 46.11% growth. Over a decade, Pfizer has delivered a strong 150.72% return, though still below the Sensex’s 183.92% appreciation. These figures underscore Pfizer’s resilience amid sector-specific challenges and broader market cycles.

Mojo Score Upgrade and Analyst Ratings

MarketsMOJO has upgraded Pfizer Ltd.’s Mojo Grade from Sell to Hold as of 03 Aug 2026, reflecting improved technical and fundamental outlooks. The current Mojo Score stands at 54.0, indicating a neutral stance with potential for upside if momentum sustains. The small-cap pharmaceutical company’s market capitalisation grade remains classified as small-cap, which may imply higher volatility but also growth opportunities within the Pharmaceuticals & Biotechnology sector.

Sectoral and Industry Positioning

Pfizer operates within the Pharmaceuticals & Biotechnology sector, which has shown signs of recovery and selective strength in recent months. The stock’s technical indicators, particularly the bullish Bollinger Bands and mildly bullish weekly MACD and Dow Theory signals, suggest that Pfizer is aligning with sectoral tailwinds. However, the mixed monthly signals and daily moving averages caution investors to monitor for potential reversals or consolidation phases.

Investment Implications and Outlook

For investors, Pfizer’s current technical profile suggests a cautious approach. The sideways trend and mixed momentum indicators imply that while short-term gains are possible, the stock has yet to establish a definitive uptrend. The lack of volume confirmation via OBV further advises prudence. Investors may consider accumulating on dips, particularly if weekly momentum indicators continue to improve and the stock breaks above key resistance levels near ₹5,000.

Long-term investors should weigh Pfizer’s historical returns against sector benchmarks and broader market conditions. The company’s three-year outperformance and decade-long gains demonstrate resilience, but the five-year underperformance highlights cyclical risks and competitive pressures within the pharmaceutical industry.

Conclusion: Navigating a Transitional Phase

Pfizer Ltd. is currently navigating a transitional technical phase characterised by a shift from bearishness to sideways momentum. The interplay of mildly bullish weekly indicators and mildly bearish monthly signals reflects a stock at a crossroads, balancing short-term optimism with longer-term caution. Investors should monitor key technical levels, volume trends, and sector developments closely to capitalise on emerging opportunities while managing downside risks.

Given the recent upgrade to a Hold rating and the stock’s relative outperformance against the Sensex in the short term, Pfizer remains a stock to watch within the Pharmaceuticals & Biotechnology sector. However, the mixed technical signals and small-cap classification suggest that a measured, research-driven approach is advisable for both traders and long-term investors.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →